PRNewsWire
28 Sept 2026, 06:10 UTC · 2h ago
Verdict
Headline takes no side. We score BE −1.00 across two claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
The complaint alleges Capricor modified the statistical analysis plan for Deramiocel without securing prior FDA agreement before resubmitting its Biologics License Application.
Newpress release dated Sep 28, 2026
More negative than 95% of claims this week
Capricor Therapeutics is facing a securities class action lawsuit alleging it made false and misleading statements regarding the clinical data analysis of its drug Deramiocel.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 85% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is mentioned as being sued for securities law violations.
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit alleging false and misleading statements regarding clinical data and FDA agreements.
More negative than 95% of ticker scores this week
The company is mentioned as being sued for securities law violations.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
—
BE hasn't traded since this ran. Last close $288.70 (Sep 25); the reaction starts at the next open.
BE chart →
